Prostate Cancer Clinical Trials in Tennessee

Showing 261-280 of 307 trials

Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants

NCT01497431

This randomized phase I trial studies the side effects and the best dose of Se-methyl-seleno-L-cysteine or selenomethionine in preventing prostate cancer in healthy participants. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of Se-methyl-seleno-L-cysteine or selenomethionine, two different types of selenium compounds, may prevent prostate cancer from forming.

No Evidence of DiseaseProstate Carcinoma

National Cancer Institute (NCI)66 participantsStarted Nov 2011

Chicago, Illinois, United States • Buffalo, New York, United States • Nashville, Tennessee, United States

COMPLETEDPhase 3157 miles

A Trial of Degarelix in Patients With Prostate Cancer

NCT00946920

A phase 3, open-label, parallel group, one year trial comparing the efficacy and safety of degarelix 3-month depot with the established therapy goserelin acetate 3-month implant in patients with prostate cancer.

Prostate Cancer

Ferring Pharmaceuticals859 participantsStarted Jun 2009

Homewood, Alabama, United States • Little Rock, Arkansas, United States • Fresno, California, United States +123 more locations

Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants

A Trial of Degarelix in Patients With Prostate Cancer

Prostate Cancer Trials in Other Cities

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer

Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling

Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Ixabepilone in Treating Patients With Metastatic Prostate Cancer

Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

3-AP in Treating Patients With Advanced Prostate Cancer

Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer

An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer

Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Other Conditions in Tennessee